Immunotherapy in Hemato-Oncology · nivolumab (at a dose of 3 mg per kilogram of body weight –hu...

Immunotherapy in Hemato-Oncology

Markus G. ManzDirector Department of Hematology and Oncology, University Hospital Zurich

markus.manz@usz.ch

ESMO PRECEPTORSHIP PROGRAMMEIMMUNO-ONCOLOGY

ZURICH, SWITZERLAND, NOVEMBER 2-3, 2018

Markus G. Manz – FINANCIAL CONFLICT OF INTEREST

• No pharma stocks/shares• Education / Advisory fees last 3 years (each <CHF 2000.-)

• Amgen, Bristol-Myers Squibb, Celgene, Janssen Pharmaceutica, Novartis, Roche, Sanofi-Aventis, Teva Pharma

• Research Support (material)• Novartis (CSF-1R inhibitors)

• Patents/Patent Aplications/Ownership• on gene-modified humanized mice• on definiton and use of spec hu hem progenitor cells• co-founder hu-mouse company

No financial COI regarding this pesentation

markus.manz@usz.ch

ESMO-Preceptorship Immuno-Oncology, Zurich November 2-3, 2018

markus.manz@usz.ch

Hematopoiesis – A Paradigmatic Stem-Cell Supported Organ

markus.manz@usz.ch

Hematopoietic Malignancies – Cell Of Origin (COO)(almost always) Systemic Diseases

AMLMDSMPN

Lymphoma

MyelomaLCHECD

Cancer Death Rates CH 2009

(Quellen für Zahlen: Zahlen Institut für Krebsepidemiologie und –Registrierung NICER)

[Prozent]

(7)(6)

Leukemia and lymphoma about 10% of all neoplasias

Inzidenz pro 100.000 Einwohner Zentraleuropa

ALL: ~1.5 / 100.000 / year

AML: ~2.5 / 100.000 / year

CLL: ~3 / 100.000 / year

CML: ~1 / 100.000 / year

„Diseases of an ageing population“

Hematopoietic Cancer Incidence

markus.manz@usz.ch

Expected scenario 2030:

Doubling of population > 65 y

Doubling of hematologic

(and other neoplasias) in

case of stable incidence

and prevalance

http://www.bfs.admin.ch/bfs/portal/de/index/themen/01/03/blank/key/ind_erw.html

Demographic Evolution in CH

markus.manz@usz.ch

• T-cell mediated

• Antibody mediated

• NK-cell mediated

• Phagocyte mediated

• Artificial, intelligent «designer-

immune» mediated

Potential Immune-Mediated Mechanisms Against Cancer

markus.manz@usz.ch

Transfer of

immune

effectors

Activation of

endogenous

immune

effectors

Mode of immune-action Mode of application

Immune-mechanisms: Antibody-mediated killing

tumor cell

NK cell

Surface Ag (e.g. CD..XY..)

Macrophage

Complement-dependentcytotoxicity

Antibody-dependentcellular cytotoxicity

Antibody-dependentcellular phagocytosis

Direct antibody-dependent toxicity

markus.manz@usz.ch

tumor cell

T cell

(Tu)Surface Ag(CD..XY..)

Dendritic cell / APC

T cell

Cytokine+ +

Cytokine++

MHC II

MHC I KILL TC!

Immune-mechanisms: T-cell mediated killing

markus.manz@usz.ch

tumor cell

T cell

Cytokine+ +

Cytokine++

MHC II

DON’T KILL TC!

markus.manz@usz.ch

tumor cell

T cell

Cytokine+ +

Cytokine++

MHC II

DON’T KILL TC!

«Enhance the Enhancers!»

-Adjuvant / Co-Stimulation

-Cytokines

-Vaccination (Peptides, DCs)

markus.manz@usz.ch

tumor cell

T cell

Cytokine+ +

Cytokine++

MHC II

DON’T KILL TC!

«Inhibit the Inhibitors!»

-mAb interference

markus.manz@usz.ch

tumor cell

T cell

Surface Ag(CD..XY..)

Immune-mechanisms: Artificial designer (immune) killing

CAR T cell

+ Conjugate or modification

Chimeric Antigen Receptor T cellSuper-armed single chain mAb

(MHC independent)

Optimized “Super”-mAb(enhanced mAb function or drug targeting)

BiTEBispecific T cell Engager

(MHC independent)

markus.manz@usz.ch

tumor cell

“don’t eat me!”

Macrophage

“eat me!”(calreticulin +…?)

Immune-mechanisms: Macrophage/Innate Checkpoint Control

markus.manz@usz.ch

EAT and KILL TC!

Overview

Immunotherapy in Hemato-Oncology (examples)

• Allogeneic hematopoietic (stem) cell transplantation

• Checkpoint control (post-allo-HSCT, HD, NHL)

• Optimized monoclonal Abs (CLL, FL, MM)

• Bispecific Abs (BiTE; ALL)

• CART cells (CD19 CART, ALL, MM; BCMA CART, MM)

• Innate Immunity Checkpoint control– CD47-SIRPa axis

markus.manz@usz.ch

CD47-SIRPa «don’t eat me» innate Immunity Checkpoint Control

Overview

markus.manz@usz.ch

Nobel-PriceMedicine

Since >50y “Bench-Mark” for any future SC therapy in regenerative medicine

markus.manz@usz.ch

Allogeneic hematopoietic (stem) cell transplantationESMO-Preceptorship Immuno-Oncology, Zurich November 2-3, 2018

HD-Chemo-/RT-Therapie

Patient

HSCDonor

Reconstruction of hematopoiesis

Active Tumor-Therapy

Infection-ProtectionGvL (GvHD against hematopoiesis)GvHD

aGvHD cGvHD

Causes of death-GvHD-Infection-Relapse

Day 14

Day 100+

markus.manz@usz.ch

therapeutic activity

Allo-HSCT: • currently only routinely applied CELLULAR immunotherapy and only clinical SC therapy

• GvL is GvHD against Hematopoiesis (+hematologic malignancy)

markus.manz@usz.ch

Overview

markus.manz@usz.ch

ESMO-Preceptorship Immuno-Oncology, Zurich Nov 4th 2017

Ipilimumab – a CTLA4-blocking mAb

Best Response Examples Ipilimumab post allo-HSCT relapse

Hodgkin’s Lymphoma

Bone Marrow

Leukemia Cutis

All seven patients (of 28) with CR or PR, as compared to patients thatdid not have a response, had someprior GvHD (p=0.08)

markus.manz@usz.ch

Checkpoint control - Hodgkin’s Lymphoma ESMO-Preceptorship Immuno-Oncology, Zurich November 2-3, 2018

n=20 responding pt

23 patients with relapsed or refractory Hodgkin’s lymphoma that had already been heavily treated receivednivolumab (at a dose of 3 mg per kilogram of body weight –hu monoclonal IgtG4 Ab against PD-1) every 2weeks until they had a complete response, tumor progression, or excessive toxic effects.

Study objectives were measurement of safety and efficacy and assessment of the PDL1 and PDL2 (alsocalled CD274 and PDCD1LG2, respectively) loci and PD-L1 and PD-L2 protein expression.

Checkpoint control - Hodgkin’s Lymphoma

markus.manz@usz.ch

ORR of >80% in r/r HD

Hodgkin’s Lymphoma Patho-Biology

markus.manz@usz.ch

• PD-L1/PD-L2 alterations

(disomy, polysomy, copy gain,

amplification) are a defining

feature of cHL

• Amplification of 9p24.1 is

more common in patients with

advanced stage disease and

associated with shorter PFS

Checkpoint inhibition in other Lymphoma(s)+MM?

markus.manz@usz.ch

Large B-cell lymphoma PD-L1 overexpression is not commonly seen on B NHL cells.ORR of 30-40% in heavily pretreated r/r DLBCL and also patients with r/r primary mediastinal large B-cell lymphoma

Mantle cell lymphoma: no larger pt group data available

Follicular lymphoma: Ten FL patients were included in a phase I study of nivolumab in a variety of r/r hematologic malignancies; the ORR was 40% and three responses were ongoing after a median follow-up of 91.4 weeks, which encouraged further clinical trials.

Chronic lymphocytic leukemia: Richter syndrome, showed an ORR of 21%

Other Lymphoma: T cell lymphoma and virus-related lymphomas (i.e. Epstein-Barr virus- or hepatitis C virus-related) might be susceptible, CNS Lymphoma, Testicular Lymphoma, Primary mediastinal B cell lymphomaMM: Trials ongoing

Overview

markus.manz@usz.ch

Antigen Expression in B Cell Maturation

markus.manz@usz.ch

CD19CD20CD22

CD38CD138BCMACD319(SLAMF7)

Expression outside ofBlood / B-Cell Compartment

- -(?)- -- -

- ++ +

mAb – aCD20 in CLL

(p=0.0001)

markus.manz@usz.ch

aCD20 mAb in all CD20+ B-cell NPL (ALL and NHL) in clinical use

As a type II antibody, GA101 binds differently than type I mAbs, leading to distinct modes of cytotoxic activity against B-cell malignancies3-6

Glycoengineering Type I/II

Complement-dependentcytotoxicity (CDC)

Antibody-dependentcellular cytotoxicity (ADCC)

Direct cell death

+++-+++

Type I antibody

(Rituximab)

Glycoengineered Type II antibody

(GA101)

Modes of action of GA101 (obinutuzumab): The first glycoengineered, type II anti-CD20 mAbOptimized mAb

markus.manz@usz.ch

Goede V, et al. N Engl J Med 2014; 370:1101–1110

Monate

MabThera + Clb

GAZYVARO + Clb

MabThera + Chlorambucil vs. GAZYVARO + Chlorambucil

Optimized mAb - CLL

markus.manz@usz.ch

1.) Study-Update EHA 2018: also significant OS benefit with longer FU 2.) FL first-line R-Chemo vs. O-Chemo (GALLIUM): longer PFS (NEJM 10/2017)

markus.manz@usz.ch

CD19CD20CD22

- -(?)- -- -

- ++ +

markus.manz@usz.ch

“Daratumumab represents a landmark advance in the treatment of myeloma. It is likely to

be incorporated into the treatment of all stages of the disease over the next several years.”

Optimized mAb – Multiple Myeloma

markus.manz@usz.ch

Optimized mAb – Multiple Myeloma

Multiple Myeloma HSPC (CD45 dim)

CD38 Expression in MM vs normal Progenitors

Delta:Therapeutic

Windowfor CD38

Targeting?

markus.manz@usz.ch

CASTOR:

DVd vs Vd

POLLUX:

DRd vs Rd

Daratumumab: New “Rituximab” for r/r MM? Better with ImID?

Optimized mAb – Relapsed/Refractory Multiple MyelomaESMO-Preceptorship Immuno-Oncology, Zurich November 2-3, 2018

Optimized mAb – first-line MM

markus.manz@usz.ch

CONCLUSIONSPatients with newly diagnosed multiple myeloma, ineligible for stem cell transplantation, daratumumabcombined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression ordeath than the same regimen without daratumumab. The daratumumab-containing regimen wasassociated with more grade 3 or 4 infections (pneumonia).

anti-CD38 mAb on way to first-line therapy in MM

Overview

• Checkpoint control (post-allo-HSCT, HD)

• Optimized monoclonal Abs (CLL, MM)

markus.manz@usz.ch

α-CD19 Blinatumomab1,2

Single-chain antibodyα-CD3

Single-chain antibody

Linker

• 55 kDa• Very short distance between arms –

allows T cells and tumour cells to come into close proximity

1. Nagorsen D, Baeuerle PA. Exp Cell Res 2011;317:1255–60;2. Baeuerle PA, Reihnardt C. Cancer Res 2009;69:4941–4;

Bispecific Ab (BiTE) - ALL

95–100% of B-precursor ALL cases are CD19+

markus.manz@usz.ch

Bispecific Ab (BiTE) - ALLESMO-Preceptorship Immuno-Oncology, Zurich November 2-3, 2018

markus.manz@usz.ch

TOWER-STUDY

markus.manz@usz.ch

Now also in first-line MRD+: 78% MRD neg; Blood 2018

TOWER-STUDY

Engineering of Antibodies

Engineering Reality – Clinical Future

Overview

markus.manz@usz.ch

New therapy for CD19+ B-ALL: CD19-CART cells

Emma Whitehead2013 20172012 NY Times 2012

Target Cell

Antigenon Cell

Binder to Antigen on

Cell CAR T cell

Target Cell

Chimeric Antigen Receptor T Cell

The principle of CAR T cell Therapy

Target Cell

Antigenon Cell

Binder to Antigen on

Target Cell

CAR T cell

Chimeric Antigen Receptor T Cell

The principle of CAR T cell Therapy

CART cells

CAR T cell

markus.manz@usz.ch

EFS OS

CD19 CART cells – r/r ALLESMO-Preceptorship Immuno-Oncology, Zurich November 2-3, 2018

markus.manz@usz.ch

On the same day as the approval, the FDA expanded the indication for tocilizumab (aIL-6R mAb), a monoclonal antibody totreat CAR T-cell–induced, severe or life-threatening CRS in patients ≥2 years of age. In clinical trials of patients treated withCAR T cells, 69 percent of patients had complete resolution of CRS within two weeks following one or two doses oftocilizumab.Sources: U.S. Food and Drug Administration news release, August 30, 2017; Novartis news release, August 30, 2017.

FDA approved the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel for the treatment of pediatric and young adult patients with B-cell precursor acute lymphocytic leukemia (ALL) that is refractory or in second or later relapse. This is the first gene therapy available in the U.S. and is “ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases,” the FDA said.

First-in-class therapy showed an 83% (52/63) overall remission rate in B-cell ALL patient population with limited treatment options and historically poor outcomes

www.novartis.com

CD19 CART cells – r/r NHLESMO-Preceptorship Immuno-Oncology, Zurich November 2-3, 2018

CD19 CART cells – r/r NHL

markus.manz@usz.ch

ZUMA-1 CTL019

CD19 CART cells – r/r NHL

Approval was based on data from the multicenter ZUMA-1 trial, which included 111 patients (median age = 58 years; range =23-76 years) with previously treated DLBCL, primary mediastinal large B-cell lymphoma, or transformed follicular lymphomafrom 22 institutions.

January 27, 2017, 101 patients (91%) had received axicabtagene ciloleucel 2×106 cells/kg, following conditioning with low-dose cytarabine and fludarabine.

ORR=72%, CR = 51% (95% CI 41-62).

Axicabtagene ciloleucelapproved for adult patients whose disease failed torespond to at least two prior treatments, as well asfor the following indications:• diffuse large B-cell lymphoma (DLBCL)• primary mediastinal large B-cell lymphoma (PMBCL)• high grade B-cell lymphoma (hgBCL)• DLBCL arising from follicular lymphoma (DLBCL

from FL)

CD19 CART cells – r/r NHLESMO-Preceptorship Immuno-Oncology, Zurich November 2-3, 2018

markus.manz@usz.ch

CD19CD20CD22

- -(?)- -- -

- ++ +

markus.manz@usz.ch

BCMA CART cells – Multiple MyelomaESMO-Preceptorship Immuno-Oncology, Zurich November 2-3, 2018

markus.manz@usz.ch

• Results demonstrate for the first time that CAR T-cells targeting an antigen other than CD19 can induce complete remissions of a hematologic malignancy.

• Importantly, CAR-BCMA T cells have powerful activity against MM that was resistant to standard therapies.

BCMA CART cells – Multiple MyelomaESMO-Preceptorship Immuno-Oncology, Zurich November 2-3, 2018

CART cells – off-the-shelf – the future?

markus.manz@usz.ch

Great Ormond Street Hospital (GOSH) and University College London:

Used cells from a healthy donor• CD19 CAR added• two genes erased (-TCR, -CD52)

CAR T cell

CD19 CAR

CAR T cell modification and combination concepts

Engineering Reality – Clinical Future

CD19 CAR T cell Therapy associated Resistance

Relapse B-ALL 7-25%

• Epitope escape

• Lineage switch

• Isoform switch/splice

variants

• CD19 mutations

• Epitope masking

Orlando EJ et al. Nat Med 2018Ruella M et al. Nat Med 2018

Overview

markus.manz@usz.ch

• SIRPa-CD47 interaction: “don’t eat me” signal• FcR-activation by tumor-bound mAb: “eat me” signal• Additional effect on APC adaptive immunity?

markus.manz@usz.ch

• Phase 1b r/r DLBCL und FL (n=22)• 2-10 prior therapies (Median=4)• 95% refraktär auf Ritxumab• 50% OR(CR + PR), 36% CR• Most freq AE: anemia, infusion reactions

• The macrophage checkpoint inhibitor 5F9 combined with rituximab showed promising activity in patients with aggressive and indolent lymphoma.

• No clinically significant safety events were observed in this initial study

markus.manz@usz.ch

Overview

An ongoing (R)Evolution

markus.manz@usz.ch

Thank you for your attention

markus.manz@usz.ch

Immunotherapy in Hemato-Oncology · nivolumab (at a dose of 3 mg per kilogram of body weight –hu...

Documents

Cardio and Hemato PPT

Atlas Hemato

Nivolumab BMS, INN-nivolumab€¦ · Nivolumab BMS . International non-proprietary name: NIVOLUMAB no Procedure No. EMEA/H/C/003840/0000 Note Assessment report as adopted by the CHMP

Hemato fundamentos

Hemato Wiener

Hemato Endocrino Nefro

Wrap Up Sk1 Hemato

Hemato Libro

Epidemiología de las Neoplasias Hemato-Oncológicas · 110 Epidemiología de las Neoplasias Hemato-Oncológicas Introducción• El concepto de enfermedades hemato-oncoló-gicas

Hemato-oncology Multiple Myeloma

Sp Hemato b6 Jos Fix (1)

Director Department of Hematology and Oncology, University ... · nivolumab (at a dose of 3 mg per kilogram of body weight –hu monoclonal IgtG4 Ab against PD-1) every 2 weeks until

NLME Hemato&RE

Biokimia Hemato

IMMUNOGLOBULIN blok hemato

Banco Hemato - 2005

Manual Hemato UNAM

International Hemato Journal

Informe TOC TOC Onco y Hemato

3rd Hemato Lab Dentistry)